Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial Quiz

A 65-year-old male patient with unresectable stage III non-small cell lung cancer (NSCLC) has completed concurrent platinum-based chemoradiotherapy without disease progression. He is currently receiving consolidation durvalumab monotherapy. His medical history includes controlled hypertension and a 40-pack-year smoking history. He has no known drug allergies and is insured with good medication adherence.

Question: Based on the updated COAST trial findings, which of the following statements best describes the potential benefit of adding oleclumab or monalizumab to durvalumab consolidation therapy in this patient?

A 70-year-old female patient with unresectable stage III NSCLC completed concurrent chemoradiotherapy and is initiating consolidation therapy. She has a history of mild chronic obstructive pulmonary disease (COPD) and well-controlled type 2 diabetes. The oncology team is considering durvalumab combined with monalizumab. The patient is concerned about potential side effects and tolerability.

Question: What counseling point regarding safety can the pharmacist provide based on the COAST trial results for this combination therapy?

A 62-year-old male patient with unresectable stage III NSCLC completed concurrent chemoradiotherapy and is discussing consolidation treatment options. He asks about the difference between durvalumab alone and durvalumab combined with oleclumab or monalizumab regarding response rates and survival benefits.

Question: How should the pharmacist explain the clinical significance of objective response rate (ORR) and overall survival (OS) findings from the COAST trial to this patient?